Long‐term efficacy of autologous cell therapy, repeated PTA and conservative treatment in people with diabetes and chronic limb‐threatening ischaemia
Authors' conclusion
Our study showed significantly longer AFS and lower major amputation rates in patients treated by ACT and re-PTA in contrast to patients treated conservatively. Overall survival was significantly longer only in the re-PTA group. ACT was shown to be effective in long-term limb salvage in people with no-option CLTI.
Study context
- Population
- Patients with diabetic foot ulcers (DFU) and chronic limb-threatening ischaemia (CLTI) (TcPO2 <30 mmHg after unsuccessful standard revascularization) treated in one foot clinic over 9 years
- Participants
- 130 patients
- Exposure
- Autologous cell therapy (ACT) vs repeated percutaneous transluminal angioplasty (re-PTA) vs conservative treatment
- ACTn = 45
- re-PTAn = 43
- Controln = 42reference
- Outcome
- Overall survival, amputation-free survival (AFS) and major amputation rate
- Follow-up
- 7-year follow-up
Methodological detailssingle foot clinic, 7-year follow-up
- Single foot clinic
- 7-year follow-up
Main finding
As reported in the abstract
AFS, major amputation and overall survival
- ACT vs Control: P < 0.001
- re-PTA vs Control: P < 0.001
- ACT vs Control: P < 0.001
- re-PTA vs Control: P < 0.001
- re-PTA vs Control: P < 0.001
- ACT vs Control: P = 0.063
- ACT vs re-PTA: P = 0.081
Observational data: associations, not effects.
Further findings
Baseline angiograms (Graziani and GLASS infrapopliteal) and TcPO2
- ACT and control had significantly worse baseline angiograms than re-PTA (both p < 0.001); no differences in baseline TcPO2
Original publication
Long‐term efficacy of autologous cell therapy, repeated PTA and conservative treatment in people with diabetes and chronic limb‐threatening ischaemia. Diabetes Obes Metab. Published 9 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →